Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD Initiative

Patrick M. Bossuyt,1* Johannes B. Reitsma,1 David E. Bruns,2,3 Constantine A. Gatsonis,4 Paul P. Glasziou,5 Les M. Irwig,6 Jeroen G. Lijmer,1 David Moher,7 Drummond Rennie,8,9 and Henrica C.W. de Vet,10 for the STARD Group

Background: To comprehend the results of diagnostic accuracy studies, readers must understand the design, conduct, analysis, and results of such studies. That goal can be achieved only through complete transparency from authors.

Objective: To improve the accuracy and completeness of reporting of studies of diagnostic accuracy to allow readers to assess the potential for bias in the study and to evaluate its generalisability.

Methods: The Standards for Reporting of Diagnostic Accuracy (STARD) steering committee searched the literature to identify publications on the appropriate conduct and reporting of diagnostic studies and extracted potential items into an extensive list. Researchers, editors, and members of professional organisations shortened this list during a two-day consensus meeting with the goal of developing a checklist and a generic flow diagram for studies of diagnostic accuracy.

Results: The search for published guidelines on diagnostic research yielded 33 previously published checklists, from which we extracted a list of 75 potential items. The consensus meeting shortened the list to 25 items, using evidence on bias whenever available. A prototypical flow diagram provides information about the method of patient recruitment, the order of test execution and the numbers of patients undergoing the test under evaluation, the reference standard or both.

Conclusions: Evaluation of research depends on complete and accurate reporting. If medical journals adopt the checklist and the flow diagram, the quality of reporting of studies of diagnostic accuracy should improve to the advantage of clinicians, researchers, reviewers, journals, and the public.

The world of diagnostic tests is highly dynamic. New tests are developed at a fast rate and the technology of existing tests is continuously being improved. Exaggerated and biased results from poorly designed and reported diagnostic studies can trigger their premature dissemination and lead physicians into making incorrect treatment decisions. A rigorous evaluation process of diagnostic tests before introduction into clinical practice could not only reduce the number of unwanted clinical consequences related to misleading estimates of test accuracy, but also limit healthcare costs by preventing unnecessary testing. Studies to determine the diagnostic accuracy of a test are a vital part in this evaluation process (1–3).

In studies of diagnostic accuracy, the outcomes from one or more tests under evaluation are compared with outcomes from the reference standard, both measured in subjects who are suspected of having the condition of interest. The term test refers to any method for obtaining additional information on a patient’s health status. It includes information from history and physical examination, laboratory tests, imaging tests, function tests and
histopathology. The condition of interest or target condition can refer to a particular disease or to any other identifiable condition that may prompt clinical actions, such as further diagnostic testing, or the initiation, modification or termination of treatment. In this framework, the reference standard is considered to be the best available method for establishing the presence or absence of the condition of interest. The reference standard can be a single method, or a combination of methods, to establish the presence of the target condition. It can include laboratory tests, imaging tests, pathology, but also dedicated clinical follow-up of subjects. The term accuracy refers to the amount of agreement between the information from the test under evaluation, referred to as the index test, and the reference standard. Diagnostic accuracy can be expressed in many ways, including sensitivity and specificity, likelihood ratios, diagnostic odds ratio, and the area under a receiver operating characteristic (ROC) curve (4–6).

There are several potential threats to the internal and external validity of a study of diagnostic accuracy. A survey of studies of diagnostic accuracy published in four major medical journals between 1978 and 1993 revealed that the methodological quality was mediocre at best (7). However, evaluations were hampered because many reports lacked information on key elements of design, conduct and analysis of diagnostic studies (7). The absence of critical information about the design and conduct of diagnostic studies has been confirmed by authors of metaanalyses (8, 9). As in any other type of research, flaws in study design can lead to biased results. One report showed that diagnostic studies with specific design features are associated with biased, optimistic, estimates of diagnostic accuracy compared to studies without such deficiencies (10).

At the 1999 Cochrane Colloquium meeting in Rome, the Cochrane Diagnostic and Screening Test Methods Working Group discussed the low methodological quality and substandard reporting of diagnostic test evaluations. The Working Group felt that the first step to correct these problems was to improve the quality of reporting of diagnostic studies. Following the successful CONSORT initiative (11–13), the Working Group aimed at the development of a checklist of items that should be included in the report of a study of diagnostic accuracy.

The objective of the Standards for Reporting of Diagnostic Accuracy (STARD) initiative is to improve the quality of reporting of studies of diagnostic accuracy. Complete and accurate reporting allows the reader to detect the potential for bias in the study (internal validity) and to assess the generalisability and applicability of the results (external validity).

**Materials and Methods**

The STARD steering committee (see appendix for membership and details) started with an extensive search to identify publications on the conduct and reporting of diagnostic studies. This search included the Medline, Embase, BIOSIS and the methodological database from the Cochrane Collaboration up to July 2000. In addition, the steering committee members examined reference lists of retrieved articles, searched personal files, and contacted other experts in the field of diagnostic research. They reviewed all relevant publications and extracted an extended list of potential checklist items.

Subsequently, the STARD steering committee convened a two-day consensus meeting for invited experts from the following interest groups: researchers, editors, methodologists and professional organisations. The aim of the conference was to reduce the extended list of potential items, where appropriate, and to discuss the optimal format and phrasing of the checklist. The selection of items to retain was based on evidence whenever possible.

The meeting format consisted of a mixture of small group sessions and plenary sessions. Each small group focused on a group of related items of the list. The suggestions of the small groups were then discussed in plenary sessions. Overnight a first draft of the STARD checklist was assembled based on the suggestions from the small group and the additional remarks from the plenary sessions. All meeting attendees discussed this version the next day and made additional changes. The members of the STARD group could suggest further changes through a later round of comments by electronic mail.

Potential users field-tested the conference version of the checklist and flow diagram and additional comments were collected. This version was placed on the CONSORT Website with a call for comments. The STARD steering committee discussed all comments and assembled the final checklist.

**Results**

The search for published guidelines for diagnostic research yielded 33 lists. Based on these published guidelines and on input of steering and STARD group members, the steering committee assembled a list of 75 items. During the consensus meeting on September 16 and 17, 2000, participants consolidated and eliminated items to form the 25-item checklist. Conference members made major revisions to the phrasing and format of the checklist.

The STARD group received valuable comments and remarks during the various stages of evaluation after the conference, which resulted in the version of the STARD checklist that appears in Table 1.

The flow diagram provides information about the method of patient recruitment (e.g., based on a consecutive series of patients with specific symptoms, case-control), the order of test execution, and the number of patients undergoing the test under evaluation (index test) and the reference test (see Fig. 1). We provide one prototypical flowchart that reflects the most commonly employed design in diagnostic research. Examples that
<table>
<thead>
<tr>
<th>Section and Topic</th>
<th>Item #</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>TITLE/ABSTRACT/KEYWORDS</td>
<td>1</td>
<td>Identify the article as a study of diagnostic accuracy (recommend MeSH heading 'sensitivity and specificity').</td>
</tr>
<tr>
<td>INTRODUCTION</td>
<td>2</td>
<td>State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between tests or across participant groups.</td>
</tr>
<tr>
<td>METHODS</td>
<td></td>
<td>Describe</td>
</tr>
<tr>
<td>Participants</td>
<td>3</td>
<td>The study population: The inclusion and exclusion criteria, setting and locations where the data were collected.</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>Participant recruitment: Was recruitment based on presenting symptoms, results from previous tests, or the fact that the participants had received the index tests or the reference standard?</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Participant sampling: Was the study population a consecutive series of participants defined by the selection criteria in items 3 and 4? If not, specify how participants were further selected.</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>Data collection: Was data collection planned before the index test and reference standard were performed (prospective study) or after (retrospective study)?</td>
</tr>
<tr>
<td>Test methods</td>
<td>7</td>
<td>The reference standard and its rationale.</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>Technical specifications of material and methods involved including how and when measurements were taken, and/or cite references for index tests and reference standard.</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>Definition of and rationale for the units, cutoffs and/or categories of the results of the index tests and the reference standard.</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>The number, training and expertise of the persons executing and reading the index tests and the reference standard.</td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>Whether or not the readers of the index tests and reference standard were blind (masked) to the results of the other test and describe any other clinical information available to the readers.</td>
</tr>
<tr>
<td>Statistical methods</td>
<td>12</td>
<td>Methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to quantify uncertainty (e.g. 95% confidence intervals).</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>Methods for calculating test reproducibility, if done.</td>
</tr>
<tr>
<td>RESULTS</td>
<td></td>
<td>Report</td>
</tr>
<tr>
<td>Participants</td>
<td>14</td>
<td>When study was done, including beginning and ending dates of recruitment.</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>Clinical and demographic characteristics of the study population (e.g. age, sex, spectrum of presenting symptoms, comorbidity, current treatments, recruitment centers).</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>The number of participants satisfying the criteria for inclusion that did or did not undergo the index tests and/or the reference standard; describe why participants failed to receive either test (a flow diagram is strongly recommended).</td>
</tr>
<tr>
<td>Test results</td>
<td>17</td>
<td>Time interval from the index tests to the reference standard, and any treatment administered between.</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>Distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in participants without the target condition.</td>
</tr>
<tr>
<td></td>
<td>19</td>
<td>A cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of the reference standard; for continuous results, the distribution of the test results by the results of the reference standard.</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>Any adverse events from performing the index tests or the reference standard.</td>
</tr>
<tr>
<td>Estimates</td>
<td>21</td>
<td>Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% confidence intervals).</td>
</tr>
<tr>
<td></td>
<td>22</td>
<td>How indeterminate results, missing responses and outliers of the index tests were handled.</td>
</tr>
<tr>
<td></td>
<td>23</td>
<td>Estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done.</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>Estimates of test reproducibility, if done.</td>
</tr>
<tr>
<td>DISCUSSION</td>
<td>25</td>
<td>Discuss the clinical applicability of the study findings.</td>
</tr>
</tbody>
</table>
reflect other designs are on the STARD Web site (see www.consort-statement.org.htm)

Discussion
The purpose of the STARD initiative is to improve the quality of the reporting of diagnostic studies. The items in the checklist and the flowchart can help authors in describing essential elements of the design and conduct of the study, the execution of tests, and the results.

We arranged the items under the usual headings of a medical research article but this is not intended to dictate the order in which they have to appear within an article.

The guiding principle in the development of the STARD checklist was to select items that would help readers to judge the potential for bias in the study and to appraise the applicability of the findings. Two other general considerations shaped the content and format of the checklist. First, the STARD group believes that one general checklist for studies of diagnostic accuracy, rather than different checklists for each field, is likely to be more widely disseminated and perhaps accepted by authors, peer reviewers, and journal editors. Although the evaluation of imaging tests differs from that of tests in the laboratory, we felt that these differences were more of degree than of kind. The second consideration was the development of a checklist specifically aimed at studies of diagnostic accuracy. We did not include general issues in the reporting of research findings, like the recommenda-
tions contained in the Uniform Requirements for Manuscripts submitted to Biomedical Journals (14).

Wherever possible, the STARD group based the decision to include an item on evidence linking the item to biased estimates (internal validity) or to variation in measures of diagnostic accuracy (external validity). The evidence varied from narrative articles explaining theoretical principles and papers presenting results from statistical modelling to empirical evidence derived from diagnostic studies. For several items, the evidence is rather limited.

A separate background document explains the meaning and rationale of each item and briefly summarises the type and amount of evidence (15). This background document should enhance the use, understanding and dissemination of the STARD checklist.

The STARD group put considerable effort into the development of a flow diagram for diagnostic studies. A flow diagram has the potential to communicate vital information about the design of a study and the flow of participants in a transparent manner (16). A comparable flow diagram has become an essential element in the CONSORT standards for reporting of randomized trials. The flow diagram could be even more essential in diagnostic studies, given the variety of designs employed in diagnostic research. Flow diagrams in the reports of diagnostic accuracy studies indicate the process of sampling and selecting participants (external validity), the flow of participants in relation to the timing and outcomes of tests, the number of subjects who fail to receive either the index test and/or the reference standard [potential for verification bias; Refs. (17–19)], and the number of patients at each stage of the study, thus providing the correct denominator for proportions (internal consistency).

The STARD group plans to measure the impact of the statement on the quality of published reports on diagnostic accuracy using a before-and-after evaluation (13). Updates of STARD will be provided when new evidence on sources of bias or variability becomes available. We welcome any comments, whether on content or form, to improve the current version.

Financial support to convene the STARD group was provided in part by the Dutch Health Care Insurance Board, the International Federation of Clinical Chemistry, the Medical Research Council’s Health Services Research Collaboration, and the Academic Medical Center in Amsterdam. This initiative to improve the reporting of studies of diagnostic accuracy was supported by a large number of people around the globe who commented on earlier versions.

Members of the STARD steering committee

**Patrick Bossuyt**
Academic Medical Center, Dept. of Clinical Epidemiology, Amsterdam, The Netherlands

**Constantine Gatsonis**
Brown University, Centre for Statistical Sciences, Providence, United States of America

**Les Irwig**
University of Sydney, Dept. of Public Health & Community Medicine, Sydney, Australia

**David Moher**
Chalmers Research Group, Ottowa, Ontario, Canada

**Riekie de Vet**
Free University, Institute for Research in Extramural Medicine, Amsterdam, The Netherlands

**David Bruns**
Clinical Chemistry, Charlottesville, United States of America

**Paul Glasziou**
Mayne Medical School, Dept. of Social & Preventive Medicine, Herston, Australia

**Jeroen Lijmer**
Academic Medical Center, Dept. of Clinical Epidemiology, Amsterdam, The Netherlands

**Drummond Rennie**
Journal of the American Medical Association, Chicago, United States of America

Members of the STARD group

Doug Altman, Institute of Health Sciences, Centre for Statistics in Medicine (Oxford, United Kingdom); Stuart Barton, British Medical Journal, BMA House (London, United Kingdom); Colin Begg, Memorial Sloan-Kettering Cancer Center, Department Epidemiology & Biostatistics (New York, NY); William Black, Dartmouth Hitchcock Medical Center, Department of Radiology (Lebanon, NH); Harry Büller, Academic Medical Center, Department of Vascular Medicine (Amsterdam, The Netherlands); Gregory Campbell, US FDA, Center for Devices and Radiological Health (Rockville, MD); Frank Davidoff, Annals of Internal Medicine (Philadelphia, PA); Jon Deeks, Institute of Health Sciences, Centre for Statistics in Medicine (Old Road, United Kingdom); Paul Dieppe, Department Social Medicine, University of Bristol (Bristol, United Kingdom); Kenneth Fleming, John Radcliffe Hospital, (Oxford, United Kingdom); Rijk van Ginkel, Academic Medical Center, Department of Clinical Epidemiology (Amsterdam, The Netherlands); Afina Glas, Academic Medical Center, Department of Clinical Epidemiology (Amsterdam, The Netherlands); Gordon Guyatt, McMaster University, Clinical Epidemiology and Biostatistics (Hamilton, Canada); James Hanley, McGill University, Department Epidemiology & Biostatistics (Montreal, Canada); Richard Horton, The Lancet, (London, United Kingdom); Myriam Hunink, Erasmus Medical Center, Department of Epidemiology & Biostatistics (Rotterdam, The Netherlands); Jos Kleijn, NHS Centre for Reviews and Dissemination (York, United Kingdom); Andre Knottnerus, Maastricht University, Netherlands School of Primary Care Research (Maastricht, The Netherlands); Erik Magid, Amager Hospital, Department of Clinical Bio-
chemistry (Copenhagen, Denmark); Barbara McNeil, Harvard Medical School, Department of Health Care Policy (Boston, MA); Matthew McQueen, Hamilton Civic Hospitals, Department of Laboratory Medicine (Hamilton, Canada); Andrew Onderdonk, Channing Laboratory (Boston, MA); John Overbeke, *Nederlands Tijdschrift voor Geneeskunde* (Amsterdam, The Netherlands); Christopher Price, St Bartholomew’s - Royal London School of Medicine and Dentistry (London, United Kingdom); Anthony Proto, *Radiology* Editorial Office (Richmond, VA); Hans Reitsma, Academic Medical Center, Department of Clinical Epidemiology (Amsterdam, The Netherlands); David Sackett, Trout Centre (Ontario, Canada); Gerard Sanders, Academic Medical Center, Department of Clinical Chemistry (Amsterdam, The Netherlands); Harold Sox, *Annals of Internal Medicine* (Philadelphia, PA); Sharon Straus, Mt. Sinai Hospital (Toronto, Canada); Stephan Walter, McMaster University, Clinical Epidemiology and Biostatistics (Hamilton, Canada).

**References**


